RNTX
What one share of Rein Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03.
Rein Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.30 |
| Dividends | $0.00 |
| Cash and investments | $0.10 |
| Book value | $0.64 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$847.04 | — | −$698.84 | $0.00 | −$5,171 |
| 2017 | $0.00 | −$60.85 | $0.38 | −$55.55 | $0.00 | $64.92 |
| 2018 | $0.00 | −$42.81 | $6.00 | −$43.90 | $0.00 | $26.58 |
| 2019 | $0.00 | −$23.94 | $0.12 | −$21.70 | $0.00 | $11.54 |
| 2021 | $0.00 | −$5.89 | $0.04 | −$5.38 | $0.00 | $9.69 |
| 2022 | $0.00 | −$6.02 | — | −$5.48 | $0.00 | $4.10 |
| 2023 | $0.00 | −$3.42 | — | −$4.31 | $0.00 | $20.12 |
| 2024 | $0.00 | −$3.51 | — | −$1.24 | $0.00 | $2.51 |
| 2025 | $0.00 | −$1.96 | — | −$0.76 | $0.00 | $0.61 |